A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (PROMADE) study.

Takashi YoshidaH KinoshitaH TaniguchiM YanishiM SugiT Matsuda

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2020)

Minodronate or denosumab can be used for preventing bone loss related to ADT in Asian patients with PCa.

Keyphrases

bone loss
bone mineral density
open label
prostate cancer
giant cell
postmenopausal women
clinical trial
study protocol
radical prostatectomy
body composition
phase ii
phase ii study
randomized controlled trial
middle aged
drug induced
rectal cancer
locally advanced